News &
Press Releases

July 17, 2026 Press Release

Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist

Vector Science & Therapeutics Corp. (TSXV: PAIN) and Caresyntax, a global leader in surgical intelligence and real-world evidence, today announced a strategic partnership to build the clinical evidence infrastructure supporting VectorMist™, Vector’s localized atomized drug delivery platform, and The LASSO Protocol™ (Laparoscopic Atomization System for Sparing Opioids).

Continue Reading

July 15, 2026 Press Release

Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies

Vector Science & Therapeutics, Corp. (TSXV: PAIN) today announced the expansion of its intellectual property portfolio to 15 patent applications developed and filed over approximately the past two years, establishing a broad technology estate centered on delivering therapeutic agents — including peptides and other biologics that are frequently difficult to administer outside the gastrointestinal tract — to the right tissue, at the right concentration, for the appropriate duration of treatment.

Continue Reading

July 7, 2026 Press Release

Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio

Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced an exclusive licensing and manufacturing agreement with LyoGenesis Plus, under which Vector licenses its proprietary biomechanical peptide delivery platform to LyoGenesis in exchange for an exclusive, long-term manufacturing relationship covering its proprietary peptide portfolio.

Continue Reading

June 8, 2026 Press Release

Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor

Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Valor Advisory Board, strengthening the Company’s leadership team as it advances its precision therapeutics platform.

Continue Reading

May 13, 2026 Press Release

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Vector Science & Therapeutics Corp. (TSXV: PAIN) has entered into an option agreement to acquire up to a 15% equity interest in LyoGenesis Plus for up to US$1,000,000, securing pharmaceutical-grade cGMP manufacturing access through an FDA-registered, 35,000 sq. ft. facility in Mequon, Wisconsin, to support its growing portfolio of 22 novel peptide formulations.

Continue Reading

May 12, 2026 Press Release

Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC

Vector Science & Therapeutics Corp. (TSXV: PAIN) announces it has entered into a three-year development and manufacturing agreement with MPP Group LLC, a key milestone advancing the Company’s therapeutic delivery platform toward commercial-scale production.

Continue Reading

May 1, 2026 Press Release

Vector Science & Therapeutics Files Provisional Patent for Novel Microneedle Catheter Platform for Intratumoral Drug Delivery

Vector Science & Therapeutics Corp. (TSXV: PAIN) announces the filing of a provisional patent application covering a novel microneedle catheter platform designed to enable precise, minimally invasive intratumoral drug delivery, advancing the Company’s site-directed therapeutic intervention portfolio.

Continue Reading

April 30, 2026 Press Release

Vector Science and Therapeutics Appoints The Honourable Tommy G. Thompson as Chairman of the Board

Vector Science and Therapeutics Corp. (TSXV: PAIN) appoints The Honourable Tommy G. Thompson, former U.S. Secretary of Health and Human Services and 42nd Governor of Wisconsin, as Chairman of the Board of Directors, bringing decades of health policy and government leadership experience.

Continue Reading

April 24, 2026 Press Release

Vector Science and Therapeutics Announces Listing on the TSX Venture Exchange

Vector Science and Therapeutics Corp. (TSXV: PAIN) announces the completion of its qualifying transaction and listing on the TSX Venture Exchange, marking a significant milestone with access to Canadian public capital markets to advance its biomechanical and transdermal drug delivery platforms.

Continue Reading

October 3, 2025 Press Release

Vector Science & Therapeutics Inc. to Reverse Merge with OpenSesame Acquisition Corp.

Vector Science & Therapeutics Inc. has entered into a definitive agreement for a reverse merger with OpenSesame Acquisition Corp., a significant step toward listing on the TSX Venture Exchange (TSXV), providing access to Canadian public capital markets.

Continue Reading